

**PRIOR AUTHORIZATION REQUEST FORM****Dasatinib (Sprycel®) / Acute myeloid leukemia (AML) in adults****DECLARATION OF THE INSURED PERSON****Section 1: Information about the participant and the patient**

Name of Participant	Insurance Policy / Certificate	Name of Employer	
Name of Patient	Date of Birth (YYYY/MM/DD)	Telephone	
Address (house number and street name)	City/Town	Province	Postal Code

Section 2: Other prescription drug insurance

Do you have other prescription drug insurance?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If so, please answer the following:		
What type of plan is it?	<input type="checkbox"/> Private	<input type="checkbox"/> Public
Have you ever submitted a claim for this drug to the other insurer?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
What is the status of the claim?	<input type="checkbox"/> Accepted	<input type="checkbox"/> Refused
		<input type="checkbox"/> Under review
Did this insurer ask you to complete a prior authorization request?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
If so, what is the status of the prior authorization request?	<input type="checkbox"/> Accepted	<input type="checkbox"/> Refused
		<input type="checkbox"/> Under review

Please enclose acceptance or refusal documents, if applicable**Section 3: Authorization to disclose personal information**

I certify that the information in this prior authorization request is complete, accurate and true.

I authorize physicians and other health care professionals, medical, paramedical or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de l'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my personal information including and without limitation any medical information and medical evaluations in connection with the processing of this request.

Photocopies of this document have the same value as the original.

Signature of **patient** (parent/legal guardian) _____ Date _____

IMPORTANT:

All correspondence concerning this form will be sent to the address indicated in the participant's file.

Send us this duly completed form by mail or by fax at: 1-855-453-3942.

Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6

**PRIOR AUTHORIZATION REQUEST FORM****Dasatinib (Sprycel[®]) / Acute myeloid leukemia (AML) in adults****DECLARATION OF THE PHYSICIAN****Section 4: Information about the prescribing physician**

Name of Physician	Specialty	Licence No.:
Telephone		Fax
I hereby certify that the information in this request is accurate:		
Signature of Physician _____		Date _____

Section 5: Drug covered by the authorization

Drug name Desatinib	Pharmaceutical form	Strength	Dosage Dose: _____ Frequency of administration: _____
Type of request	<input type="checkbox"/> First request Complete Section 6		
	<input type="checkbox"/> Continuation of treatment Complete Section 7 Also complete Section 6 if this is the first authorization requested from SSQ		



PRIOR AUTHORIZATION REQUEST FORM

Dasatinib (Sprycel[®]) / Acute myeloid leukemia (AML) in adults

Section 6: Clinical information (first request)

Diagnosis

Acute myeloid leukemia (AML) in adults

☐ **With** Philadelphia chromosome (Ph+)

☐ **Without** Philadelphia chromosome

CURRENT performance status

ECOG ☐ 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4

Summary of previous imatinib trials

IMATINIB (from _____ to _____) ☐ Failure ☐ Intolerance ☐ Contraindication ☐ Other

Specify: _____

Section 7: Clinical information (continuation of treatment)

Hematologic response

☐ Yes. Elements of hematologic response observed: _____

☐ No. Expected clinical benefits from continuing this treatment: _____

Section 8: Additional information
